Posted by Michael Wonder on 24 Sep 2018
Sun Pharma announces Australian TGA approval of Ilumya (tildrakizumab) for treatment of moderate-to-severe plaque psoriasis
21 September 2018 - Sun Pharma today announced that it has received the Australian TGA approval for its speciality product, Ilumya (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
The TGA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multi-centre, randomised, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 1862 adult patients were enrolled and treated with Ilumya (N=1238), etanercept (N=313) or placebo (N=310).
